Sangamo said it plans to explore all options to commercialise the asset, including seeking a potential new collaboration partner.

Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.

BLB-101 is under clinical development by Blue Lake Biotechnology and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Solid Tumor.

Ligufalimab is under clinical development by Akeso and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC).

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

PTS-500 is under clinical development by Gongwin Biopharm and currently in Phase II for Non-Small Cell Lung Cancer.

Xaluritamig is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...

HMPL-306 is under clinical development by Hutchison MediPharma and currently in Phase I for Myeloproliferative Disorders.

Vebreltinib DR is under clinical development by Apollomics and currently in Phase II for Non-Small Cell Lung Cancer.

ZX-4081 is under clinical development by Hangzhou Zenshine Pharmaceuticals and currently in Phase I for Melanoma.

A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...